73 related articles for article (PubMed ID: 374647)
1. Investigations in mice on the potentiation of resistance to infections by a new immunostimulant compound.
Bicker U; Ziegler AE; Hebold G
J Infect Dis; 1979 Apr; 139(4):389-95. PubMed ID: 374647
[TBL] [Abstract][Full Text] [Related]
2. Animal experiments on the compensation of the immunosuppressive action of cyclophosphamide by 2-[-2-cyanaziridinyl-(1)-]-2-[-2-carbamoylaziridinyl-(1)]-propane BM 12 531.
Bicker U; Hebold G; Ziegler AE; Maus W
Exp Pathol (Jena); 1978; 15(1):49-62. PubMed ID: 346364
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effects of BM 12,531 (Prop. INN azimexon).
Bicker U
Recent Results Cancer Res; 1980; 75():147-52. PubMed ID: 7232826
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulating effects of BM 12.531 in animals and tolerance in man.
Bicker U
Cancer Treat Rep; 1978 Nov; 62(11):1987-96. PubMed ID: 728913
[TBL] [Abstract][Full Text] [Related]
5. The immunomodulatory effect on BM 12.531 (azimexon) on normal or tumored mice: in vitro and in vivo studies.
Stylos WA; Chirigos MA; Papademetriou V; Lauer L
J Immunopharmacol; 1980; 2(1):113-32. PubMed ID: 7452003
[TBL] [Abstract][Full Text] [Related]
6. Reduction of acute toxicity of cyclophosphamide and X-rays by the new immunomodulating compound BM 12.531.
Bicker U; Friedberg KD; Hebold G; Mengel K
Experientia; 1979 Oct; 35(10):1361-3. PubMed ID: 499423
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of host defence by Y-19995 (2,4'-bis(1-methyl-2-dimethyl-aminoethoxyl)-3-benzoylpyridine dimaleate), a novel synthetic compound. I. Accelerated restoration from the leukocytopenia and augmented protection against microbial infections in immunocompromised mice.
Fujisawa H; Tsuru S; Hisatome M; Goto K; Oe T; Okumoto T; Taniguchi M; Nomoto K
J Clin Lab Immunol; 1987 Aug; 23(4):203-8. PubMed ID: 3312612
[TBL] [Abstract][Full Text] [Related]
8. Effects of a new antibiotic, isohematinic acid, on the resistance of mice to experimental infections.
Shiraishi A; Katayama T; Matsuda T; Itoh Y; Haneishi T
Microbiol Immunol; 1987; 31(5):461-8. PubMed ID: 3309579
[TBL] [Abstract][Full Text] [Related]
9. Influence of cyclophosphamide (Endoxan) and azimexone (BM 12.531), 2-[2-Cyanaziridinyl-(1)]-2-[2-carbamoylaziridinyl-(1)]-propane, on the bone marrow cells of mice.
Adam M; Ernst H; Bicker U
Exp Pathol; 1981; 19(1):1-14. PubMed ID: 7262269
[No Abstract] [Full Text] [Related]
10. Influence of genetic factors on natural resistance of mice to Pseudomonas aeruginosa.
Pennington JE; Williams RM
J Infect Dis; 1979 Apr; 139(4):396-400. PubMed ID: 108343
[TBL] [Abstract][Full Text] [Related]
11. Immunomodulation by the new synthetic compound BM 12.531, 2-[2-cyanaziridinyl-(1)]-[2-carbamoylaziridinyl-(1)]-propane (azimexone).
Luckenbach GA; Cortez-Campeao D; Modolell ML; Munder PG; Bicker U
Exp Pathol; 1981; 19(1):37-48. PubMed ID: 7262272
[No Abstract] [Full Text] [Related]
12. Experimental Escherichia coli 06 infection in mice. II. Protective factors of immunity after immunosuppression.
Ahlstedt S
Scand J Infect Dis Suppl; 1980; Suppl 24():216-9. PubMed ID: 7010558
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of a Fixed Combination of Tetracycline, Chloramphenicol, and Colistimethate Sodium for Treatment of Candida albicans Keratitis.
Blanco AR; Nostro A; D'Angelo V; D'Arrigo M; Mazzone MG; Marino A
Invest Ophthalmol Vis Sci; 2017 Aug; 58(10):4292-4298. PubMed ID: 28846777
[TBL] [Abstract][Full Text] [Related]
14. [Combined chemotherapy of experimental infection in neutropenia].
Viadro MM; Ivanitskaia LP; Samoĭlova LN; Kudinova MK; Bodunkova LE
Antibiot Khimioter; 1989 May; 34(5):378-82. PubMed ID: 2662929
[TBL] [Abstract][Full Text] [Related]
15. [Characteristics of the increased resistance of mice to Pseudomonas aeruginosa caused by Staphylococcus aureus].
Mathieu LG; deRepentigny J; Gadbois T
Can J Microbiol; 1976 Dec; 22(12):1734-42. PubMed ID: 827329
[TBL] [Abstract][Full Text] [Related]
16. Single-organism model of host defense against infection: a novel immunotoxicologic approach to evaluate immunomodulatory drugs.
Herzyk DJ; Ruggieri EV; Cunningham L; Polsky R; Herold C; Klinkner AM; Badger A; Kerns WD; Bugelski PJ
Toxicol Pathol; 1997; 25(4):351-62. PubMed ID: 9280118
[TBL] [Abstract][Full Text] [Related]
17. TLR-2, IL-10 and IL-17-mediated immunity in experimental chemotherapy murine model of systemic candidiasis; cyclophosphamides' impact and roles.
Dehghan P; Tolouie S; Baradaran B; Nami S; Morovati H
Microb Pathog; 2018 Jun; 119():183-192. PubMed ID: 29673975
[TBL] [Abstract][Full Text] [Related]
18. [Effect of phosphemide and forpurine on antibody formation].
Vatin AE; Popova GE
Farmakol Toksikol; 1977; 40(5):582-5. PubMed ID: 562775
[TBL] [Abstract][Full Text] [Related]
19. [Immunomodulating therapy of adjuvant disease in rats using cyclophosphamide in combination with prodigiozan--its effect on anti-infectious resistance].
Sibiriak SV; Lazareva DN; Khaĭbullina SF
Antibiot Khimioter; 1988 Jul; 33(7):532-5. PubMed ID: 3056303
[TBL] [Abstract][Full Text] [Related]
20. [Phagocytic immunity in white mice with Pseudomonas aeruginosa-induced sepsis treated with gentamicin and pentoxyl].
Alekseev AM
Mikrobiol Zh; 1976; 38(1):86-8. PubMed ID: 823397
[No Abstract] [Full Text] [Related]
[Next] [New Search]
